Signals, Powered By EquityPandit
The USFDA has provided its approval to Glenmark Pharmaceuticals USA for Clobetasol Propionate Ointment that is used in treating various skin conditions.
The company has said in a BSE filing that “Glenmark Pharmaceuticals Inc, USA has been granted final approval by the USFDA for Clobetasol Propionate Ointment USP, 0.05 percent.”
The product which has got the approval is a generic version of Fougera Pharmaceuticals Inc’s Temovate Ointment, 0.05 percent.
According to the IMS Health sales data for the 12 month period ended January 2017, the Temovate Ointment, 0.05 percent market achieved annual sales of approximately USD 175.3 million.
